Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > REGULATORY
REGULATORY
- MHLW to Require CTD-Based Submissions for Generics, Effective March 2017
March 15, 2016
- Sales Thresholds for Re-Pricing Rule to Be Key Point of Future Discussions: MHLW Pharma Management Director
March 15, 2016
- MHLW Panel Launches Discussions on New Basic Plan against Cancer
March 14, 2016
- MHLW Panel Roughly OKs Use of MID-NET Database by Drug Makers
March 14, 2016
- No Licensing Deal Clinched for First AMED-Backed Drug Seed
March 14, 2016
- MHLW’s Info Gathering System for Pediatric Drugs Goes Live
March 14, 2016
- Japan to Lead Initiatives to Disseminate Regulatory Submission, Review Rules in APEC
March 14, 2016
- MHLW Wants to Continue Price Maintenance Scheme for On-Patent Drugs: Shiozaki
March 11, 2016
- Shiozaki Seeks Understanding for “Huge-Seller” Drug Re-Pricing
March 11, 2016
- Drug Makers Should Have Freewheeling Discussions towards 2018 Reform, MHLW Wants to Pick Their Brains: Official
March 10, 2016
- “Huge Seller” Re-Pricing Dominates Discussions at LDP Study Group
March 10, 2016
- 76 Products Join Japanese Pharmacopoeia: MHLW
March 10, 2016
- Difficult to Enact Clinical Research Bill in Current Diet Session: LDP Health Panel Chief
March 9, 2016
- PMDA Aims to Complete Reviews for 70% of Priority Products within 9 Months in FY2016
March 9, 2016
- MHLW Sorts Out Schemes for Humanitarian Trials, Patient-Initiated Mixed Care
March 8, 2016
- 77.8% of Generics Converge into Single Price Brand in FY2016 Revision: MHLW
March 7, 2016
- Drug Damage Watchdog Says NOAC Makers Paid Big for People Involved in AF Guidelines
March 7, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for February
March 4, 2016
- MHLW Panel Sets Official Price of Raw Plasma for Coagulation Factor Products at 11,100 Yen per Liter
March 4, 2016
- 439 APIs/1,057 Long-Listed Products Subject to Z2 Price Cut Rule in FY2016 Revisions
March 4, 2016
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…